Photo from wikipedia
Abstract We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction… Click to show full abstract
Abstract We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.
Keywords:
secondary infections;
coronavirus disease;
treatment coronavirus;
reduction secondary;
associated reduction;
treatment
Journal Title: Open Forum Infectious Diseases
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Open Forum Infectious Diseases
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!